Table 3.

Multivariate analysis of the association between patients' characteristics and T790M status of rebiopsy

Characteristic	Odds ratio (95% CI)	p-valuea)	Adjusted odds ratio (95% CI)	p-valuea)
Baseline EGFR mutation status
19Del vs. others	2.15 (1.23-3.78)	0.008	2.14 (1.20-3.83)	0.010b)
PFS of first-line TKI
> 11 mo vs. ≤ 11 mo	1.82 (1.05-3.18)	0.034	1.82 (1.02-3.25)	0.044c)
Rebiopsy site
Metastasis vs. primary	2.17 (1.19-3.97)	0.012	1.97 (1.06-3.67)	0.032d)

CI, confidence interval; EGFR, epidermal growth factor receptor; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.

^a)By logistic regression model,

^b)Adjusted by age, sex, rebiopsy site, PFS of first-line TKI,

^c)Adjusted by age, sex, rebiopsy site, and baseline EGFR mutation status,

^d)Adjusted by age, sex, PFS of first-line TKI and baseline EGFR mutation status.